What are the recommended medications for gastrointestinal dysmotility?

Medications for Gastrointestinal Dysmotility

For severe chronic small intestinal dysmotility, prucalopride (a selective 5-HT4 receptor agonist) is the preferred first-line prokinetic agent because it lacks the cardiac risks of withdrawn alternatives and does not prolong the QT interval, while erythromycin (900 mg/day) or azithromycin should be used when absent or impaired migrating motor complexes are documented, though tachyphylaxis limits long-term erythromycin use. 1

Prokinetic Agents: The Core Treatment

First-Line Options

• Prucalopride: This high-affinity selective 5-HT4 receptor agonist is the safest prokinetic currently available. Unlike cisapride and tegaserod (both withdrawn for cardiac risks), prucalopride does not affect the QT interval and has no significant action on cardiac potassium channels. It particularly helps with constipation and vomiting. 1

• Erythromycin: As a motilin agonist, use 900 mg/day when manometry shows absent or impaired antroduodenal migrating complexes. The major limitation is tachyphylaxis with prolonged use. Azithromycin may be more effective for small bowel dysmotility specifically. 1

Agents to Use With Extreme Caution or Avoid

Metoclopramide and domperidone (D2 dopamine receptor antagonists) can stimulate gastric emptying but have serious safety concerns:

• Metoclopramide causes extrapyramidal side effects (especially in children) and potentially irreversible tardive dyskinesia in elderly patients
• The European Medicines Agency recommends against long-term metoclopramide use due to lack of consistent benefit in gastroparesis
• Domperidone requires QTc monitoring due to prolonged QTc risk per National Patient Safety Agency alerts 1

Critical safety note: Cisapride and tegaserod were withdrawn—cisapride for fatal cardiac arrhythmias and tegaserod for increased heart attacks/strokes. Never use these agents. 1

Second-Line and Rescue Therapies

Octreotide: The Rescue Agent

Octreotide (50-100 μg subcutaneously once or twice daily) can be dramatically beneficial, especially in systemic sclerosis when other treatments fail. It:

• Improves vomiting and pain within 48 hours
• Effects are maintained for over 2 years
• May restore low amplitude migrating motor complexes
• Works when erythromycin has failed
• Can be combined with erythromycin for enhanced effect 1

The main drawback is the relatively painful subcutaneous injection route.

Parasympathomimetics

Bethanechol, distigmine, neostigmine, and pyridostigmine enhance parasympathetic gut activity but are rarely used due to severe gastrointestinal and cardiovascular side effects (diarrhea, severe bradycardia). However, pyridostigmine has shown benefit for refractory constipation (including in diabetes) using a stepped dosing regimen. 1

Symptom-Specific Management

For Constipation-Predominant Dysmotility

Follow this escalation algorithm 1:

1. Start with osmotic laxatives: Macrogols (polyethylene glycol), lactulose, or magnesium salts
2. Add stimulant laxatives if inadequate response: Senna or bisacodyl (avoid in intestinal obstruction)
3. Consider prucalopride: Particularly effective for chronic constipation
4. Methylnaltrexone or naloxegol: For opioid-induced constipation (peripherally acting mu-opioid receptor antagonists that don't affect central analgesia)

For Nausea and Vomiting

• Ondansetron (4-8 mg 2-3 times daily) or granisetron (1 mg twice daily): 5-HT3 receptor antagonists are first-line 2
• Aprepitant (80-125 mg/day): NK-1 receptor antagonist may benefit up to one-third of patients with troublesome nausea 2
• Phenothiazines (prochlorperazine 5-10 mg four times daily, chlorpromazine 10-25 mg 3-4 times daily) inhibit dopamine receptors in the brain 2

For Opioid-Related Dysmotility

Naloxone 1.6 mg subcutaneously daily or methylnaltrexone subcutaneously on alternate days blocks dysmotility effects of opioids or improves motility through blocking endogenous opioids. 1

Treating Underlying Conditions

When autoimmune myopathy is identified, prednisolone and ciclosporin have particular benefit based on case series. 1 Optimize diabetic control (may require insulin pump), and correct any electrolyte, mineral, or endocrine abnormalities. 1

Critical Pitfalls to Avoid

1. Don't use prokinetics after bowel anastomosis 1
2. Monitor QTc with long-term domperidone use 1
3. Avoid metoclopramide in elderly patients (tardive dyskinesia risk) and children (extrapyramidal effects) 1
4. Recognize that drug therapy targets the most bothersome symptom—you may need conflicting medications (prokinetic for constipation AND anticholinergic for colicky pain) 1
5. Erythromycin loses effectiveness over time due to tachyphylaxis 1

Evidence Quality Note

The 2020 Gut guidelines 1 represent the most authoritative source, though they acknowledge the evidence base is limited to case series for many interventions. The 2022 AGA Clinical Practice Update 2 provides complementary guidance specifically for gastroparesis. Meta-analysis data 3 confirms dopamine receptor antagonists and macrolides significantly improve GI motility, though safety concerns limit their use.